4D Molecular Therapeutics (FDMT) Current Deferred Revenue (2019 - 2025)
Historic Current Deferred Revenue for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to $360000.0.
- 4D Molecular Therapeutics' Current Deferred Revenue fell 7262.36% to $360000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $360000.0, marking a year-over-year decrease of 7262.36%. This contributed to the annual value of $257000.0 for FY2024, which is 586.08% down from last year.
- Per 4D Molecular Therapeutics' latest filing, its Current Deferred Revenue stood at $360000.0 for Q3 2025, which was down 7262.36% from $1.1 million recorded in Q2 2025.
- In the past 5 years, 4D Molecular Therapeutics' Current Deferred Revenue ranged from a high of $18.8 million in Q1 2021 and a low of $257000.0 during Q4 2024
- In the last 5 years, 4D Molecular Therapeutics' Current Deferred Revenue had a median value of $1.4 million in 2023 and averaged $3.0 million.
- Per our database at Business Quant, 4D Molecular Therapeutics' Current Deferred Revenue crashed by 8607.14% in 2023 and then surged by 725.94% in 2024.
- Quarter analysis of 5 years shows 4D Molecular Therapeutics' Current Deferred Revenue stood at $5.1 million in 2021, then crashed by 61.49% to $2.0 million in 2022, then plummeted by 86.07% to $273000.0 in 2023, then fell by 5.86% to $257000.0 in 2024, then soared by 40.08% to $360000.0 in 2025.
- Its Current Deferred Revenue was $360000.0 in Q3 2025, compared to $1.1 million in Q2 2025 and $866000.0 in Q1 2025.